Chronic graft-versus-host disease

Cutler, 2001, Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis, J Clin Oncol, 19, 3685, 10.1200/JCO.2001.19.16.3685

Lee, 2005, New approaches for preventing and treating chronic graft-versus-host disease, Blood, 105, 4200, 10.1182/blood-2004-10-4023

Weisdorf, 2005, Chronic graft-versus-host disease: where is promise for the future?, Leukemia, 19, 1532, 10.1038/sj.leu.2403856

Lee, 2002, Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse, Blood, 100, 406, 10.1182/blood.V100.2.406

Socie, 1999, Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry, N Engl J Med, 341, 14, 10.1056/NEJM199907013410103

Ho, 2001, The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation, Blood, 98, 3192, 10.1182/blood.V98.12.3192

Guglielmi, 2002, Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose, Blood, 100, 397, 10.1182/blood.V100.2.397

Porter, 1999, Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions, Biol Blood Marrow Transplant, 5, 253, 10.1053/bbmt.1999.v5.pm10465105

Porter, 2000, Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions, Blood, 95, 1214

Falkenburg, 2003, Minor histocompatibility antigens in human stem cell transplantation, Exp Hematol, 31, 743, 10.1016/S0301-472X(03)00190-5

Miklos, 2004, Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors, Blood, 103, 353, 10.1182/blood-2003-03-0984

Miklos, 2005, Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission, Blood, 105, 2973, 10.1182/blood-2004-09-3660

Zorn, 2004, Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation, J Exp Med, 199, 1133, 10.1084/jem.20031560

Cai, 2004, Minor H antigen HA-1-specific regulator and effector CD8+ T cells, and HA-1 microchimerism, in allograft tolerance, J Exp Med, 199, 1017, 10.1084/jem.20031012

Parkman, 1989, Graft-versus-host disease: an alternative hypothesis, Immunol Today, 10, 362, 10.1016/0167-5699(89)90267-3

Tivol, 2005, Emergent autoimmunity in graft-versus-host disease, Blood, 105, 4885, 10.1182/blood-2004-12-4980

Cutler, 2005, Rituxan for steroid-refractory chronic GVHD [abstract]., Biol Blood Marrow Transplant, 11s, 10, 10.1016/j.bbmt.2004.12.030

Ratanatharathorn, 2003, Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody, Biol Blood Marrow Transplant, 9, 505, 10.1016/S1083-8791(03)00216-7

Schetelig, 2003, Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group, J Clin Oncol, 21, 2747, 10.1200/JCO.2003.12.011

Sorror, 2005, Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia, J Clin Oncol, 23, 3819, 10.1200/JCO.2005.04.569

Shulman, 1980, Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients, Am J Med, 69, 204, 10.1016/0002-9343(80)90380-0

Lee, 2002, Development and validation of a scale to measure symptoms of chronic graft-versus-host disease, Biol Blood Marrow Transplant, 8, 444, 10.1053/bbmt.2002.v8.pm12234170

Akpek, 2003, Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study, Blood, 102, 802, 10.1182/blood-2002-10-3141

Kansu, 2001, Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial, Blood, 98, 3868, 10.1182/blood.V98.13.3868

Mengarelli, 2003, One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation, Haematologica, 88, 315

Bacigalupo, 1990, Cyclosporin A and chronic graft versus host disease, Bone Marrow Transplant, 6, 341

Lonnqvist, 1990, Long-term cyclosporin therapy may decrease the risk of chronic graft-versus-host disease, Br J Haematol, 74, 547, 10.1111/j.1365-2141.1990.tb06356.x

Ruutu, 1988, Low incidence of severe acute and chronic graft-versus-host disease as a result of prolonged cyclosporine prophylaxis and early aggressive treatment with corticosteroids, Transplant Proc, 20, 491

Koc, 2002, Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone, Blood, 100, 48, 10.1182/blood.V100.1.48

Arora, 2001, Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease, Biol Blood Marrow Transplant, 7, 265, 10.1053/bbmt.2001.v7.pm11400948

Koc, 2000, Thalidomide for treatment of patients with chronic graft-versus-host disease, Blood, 96, 3995, 10.1182/blood.V96.12.3995

Lopez, 2005, Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease, Biol Blood Marrow Transplant, 11, 307, 10.1016/j.bbmt.2005.01.011

Kim, 2004, Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant, Eur J Haematol, 73, 56, 10.1111/j.1600-0609.2004.00247.x

Busca, 2003, Response to mycophenolate mofetil therapy in refractory chronic graft-versus-host disease, Haematologica, 88, 837

Baudard, 2002, Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients, Bone Marrow Transplant, 30, 287, 10.1038/sj.bmt.1703633

Mookerjee, 1999, Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus, Bone Marrow Transplant, 24, 517, 10.1038/sj.bmt.1701936

Johnston, 2005, Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease, Biol Blood Marrow Transplant, 11, 47, 10.1016/j.bbmt.2004.10.004

Couriel, 2005, Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease, Br J Haematol, 130, 409, 10.1111/j.1365-2141.2005.05616.x

Antin, 2003, Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation, Blood, 102, 1601, 10.1182/blood-2003-02-0489

Cutler, 2004, Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation, Biol Blood Marrow Transplant, 10, 328, 10.1016/j.bbmt.2003.12.305

Kulkarni, 2003, Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease, Bone Marrow Transplant, 32, 165, 10.1038/sj.bmt.1704033

Browne, 2000, Response to thalidomide therapy in refractory chronic graft-versus-host disease, Bone Marrow Transplant, 26, 865, 10.1038/sj.bmt.1702626

Parker, 1995, Thalidomide as salvage therapy for chronic graft-versus-host disease, Blood, 86, 3604, 10.1182/blood.V86.9.3604.bloodjournal8693604

Vogelsang, 1992, Thalidomide for the treatment of chronic graft-versus-host disease, N Engl J Med, 326, 1055, 10.1056/NEJM199204163261604

Ratanatharathorn, 2000, Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease, Ann Intern Med, 133, 275, 10.7326/0003-4819-133-4-200008150-00011

Canninga-van Dijk, 2004, Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease, Blood, 104, 2603, 10.1182/blood-2004-05-1855

Mayer, 2005, Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease, Bone Marrow Transplant, 35, 699, 10.1038/sj.bmt.1704829

Gilman, 2000, Hydroxychloroquine for the treatment of chronic graft-versus-host disease, Biol Blood Marrow Transplant, 6, 327, 10.1016/S1083-8791(00)70058-9

Akpek, 2001, A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease, Biol Blood Marrow Transplant, 7, 495, 10.1053/bbmt.2001.v7.pm11669216

Gorgun, 2002, Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease, Blood, 100, 941, 10.1182/blood-2002-01-0068

Foss, 2002, Extracorporeal photopheresis in chronic graft-versus-host disease, Bone Marrow Transplant, 29, 719, 10.1038/sj.bmt.1703529

Foss, 2005, Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors, Bone Marrow Transplant, 35, 1187, 10.1038/sj.bmt.1704984

Seaton, 2003, Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response, Blood, 102, 1217, 10.1182/blood-2002-11-3351

Apisarnthanarax, 2003, Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results, Bone Marrow Transplant, 31, 459, 10.1038/sj.bmt.1703871